Cost-utility analyses of diagnostic laboratory tests: A systematic review

Value in Health

Volumn 14, Issue 8, 2011, Pages 1010-1018

  Fang, Chihui ^a   Otero, Hansel J ^a   Greenberg, Dan ^a,b   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

cost effectiveness; cost utility; diagnostics; laboratory tests; QALY

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; LABORATORY TEST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK ASSESSMENT; SAFETY; SYSTEMATIC REVIEW;

EID: 82955193785     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.05.044     Document Type: Article

References (64)

1. T. Kobayashi, R. Goto, K. Ito, K. Mitsumori Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective Eur J Surg Oncol 33 2007 783 789 (Pubitemid 47029676)
2. Thomson Reuters Waste in the US Healthcare System Pegged at $700 Billion in Report from Thomson Reuters http://thomsonreuters.com/content/press- room/tsh/waste-US-healthcare-system [Accessed July 8, 2011]
3. W.C. van, C.D. Naylor Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits JAMA 280 1998 550 558
4. C. Gluud, L.L. Gluud Evidence based diagnostics BMJ 330 2005 724 726 (Pubitemid 40470021)
5. P.J. Neumann Using Cost-Effectiveness Analysis to Improve Health Care 2005 Oxford University Press New York, New York
6. P.J. Neumann, A.B. Rosen, M.C. Weinstein Medicare and cost-effectiveness analysis N Engl J Med 353 2005 1516 1522 (Pubitemid 41400929)
7. A.M. Garber Cost-effectiveness and evidence evaluation as criteria for coverage policy Health Aff (Millwood) 2004 Suppl Web Exclusives:W4-284-96.:W4-96
8. A. Harris, M. Buxton, B. O'Brien, F.R. Drummond Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries Expert Rev Pharmacoecon Outcomes Res 1 2001 7 12 (Pubitemid 34649740)
9. S.D. Ramsey, D.L. Veenstra, L.P. Garrison Jr. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests Am J Manag Care 12 2006 197 202
10. S.P. O'Malley The Australian experiment: the use of evidence based medicine for the reimbursement of surgical and diagnostic procedures (1998-2004) Aust New Zealand Health Policy 3 2006 3
11. M.F. Drummond, A.R. Mason European perspective on the costs and cost-effectiveness of cancer therapies J Clin Oncol 25 2007 191 195 (Pubitemid 350003033)
12. M.F. Drummond, B. O'Brien, G.L. Stoddart, G.W. Torrance Methods for the Econonmic Evaluation of Health Care Programmes 2003 Oxford University Press Oxford, England
13. W.S. Weintraub, D.J. Cohen The limits of cost-effectiveness analysis Circ Cardiovasc Qual Outcomes 2 2009 55 58
14. L.C. Baker, S.W. Atlas, C.C. Afendulis Expanded use of imaging technology and the challenge of measuring value Health Aff (Millwood) 27 2008 1467 1478
15. S.D. Grosse, S. Wordsworth, K. Payne Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis Genet Med 10 2008 648 654
16. D.W. Lee, P.J. Neumann, J.A. Rizzo Understanding the medical and nonmedical value of diagnostic testing Value Health 13 2010 310 314
17. L.M. Schwartz, S. Woloshin, F.J. Fowler Jr. , H.G. Welch Enthusiasm for cancer screening in the United States JAMA 291 2004 71 78 (Pubitemid 38040537)
18. P.J. Neumann, C.H. Fang, J.T. Cohen 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement Pharmacoeconomics 27 2009 861 872
19. C.A. Brauer, P.J. Neumann, A.B. Rosen Trends in cost effectiveness analyses in orthopaedic surgery Clin Orthop Relat Res 457 2007 42 48 (Pubitemid 46573395)
20. C.A. Brauer, A.B. Rosen, N.V. Olchanski, P.J. Neumann Cost-utility analyses in orthopaedic surgery J Bone Joint Surg Am 87 2005 1253 1259 (Pubitemid 40756625)
21. H.J. Otero, F.J. Rybicki, D. Greenberg, P.J. Neumann Twenty years of cost-effectiveness analysis in medical imaging: are we improving? Radiology 249 2008 917 925
22. H.J. Otero, F.J. Rybicki, D. Greenberg, D. Mitsouras, J.A. Mendoza, P.J. Neumann Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money? Int J Cardiovasc Imaging 26 2010 605 612
23. W.K. Redekop Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database Expert Rev Pharmacoecon Outcomes Res 6 2006 41 48
24. Tufts Medical Center Cost-Effectiveness Analysis Registry http://www.cearegistry.org 2010 [Accessed June 15, 2011]
25. D. Talmor, D. Greenberg, M.D. Howell, A. Lisbon, V. Novack, N. Shapiro The costs and cost-effectiveness of an integrated sepsis treatment protocol Crit Care Med 36 2008 1168 1174 (Pubitemid 351482666)
26. D. Greenberg, C. Earle, C.H. Fang, A. Eldar-Lissai, P.J. Neumann When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology J Natl Cancer Inst 102 2010 82 88
27. Task Force on Principles for Economic Analysis of Health Care Technology Economic analysis of health care technology A report on principles Ann Intern Med 123 1995 61 70
28. M.F. Drummond, W.S. Richardson, B.J. O'Brien, M. Levine, D. Heyland Users' guides to the medical literature XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group JAMA 277 1997 1552 1557 (Pubitemid 27213306)
29. M.F. Drummond, T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ The BMJ Economic Evaluation Working Party BMJ 313 1996 275 283 (Pubitemid 26254740)
30. D. Menon, F. Schubert, G.W. Torrance Canada's new guidelines for the economic evaluation of pharmaceuticals Med Care 34 12 Suppl 1996 DS77 DS86
31. B.J. O'Brien, D. Heyland, W.S. Richardson, M. Levine, M.F. Drummond Users' guides to the medical literature XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group JAMA 277 1997 1802 1806 (Pubitemid 27247167)
32. U.S. National Library of Medicine Laboratory Tests MedlinePlus 2010 Ref Type: Electronic Citation
33. A. Coco The cost-effectiveness of expanded testing for primary HIV infection Ann Fam Med 3 2005 391 399 (Pubitemid 41512655)
34. S.S. Raab, J. Hornberger The effect of a patient's risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions Chest 111 1997 1583 1590 (Pubitemid 27260087)
35. P. Tappenden, J. Chilcott, S. Eggington, J. Patnick, H. Sakai, J. Karnon Option appraisal of population-based colorectal cancer screening programmes in England Gut 56 2007 677 684 (Pubitemid 46662935)
36. A. Pereira Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union Transfusion 43 2003 192 201 (Pubitemid 36207299)
37. G.S. Ginsburg, J.J. McCarthy Personalized medicine: revolutionizing drug discovery and patient care Trends Biotechnol 19 2001 491 496 (Pubitemid 33063607)
38. M.L. DeKay, D.A. Asch Is the defensive use of diagnostic tests good for patients, or bad? Med Decis Making 18 1998 19 28 (Pubitemid 28041634)
39. D.A. Asch, J.P. Patton, J.C. Hershey Knowing for the sake of knowing: the value of prognostic information Med Decis Making 10 1990 47 57 (Pubitemid 20086096)
40. D.G. Fryback, J.R. Thornbury The efficacy of diagnostic imaging Med Decis Making 11 1991 88 94
41. J. Shogren Economics of diet and health: research challenges Food Economics: Acta Agriculture Scandinavica 2 Section C 2005 117 127 Ref Type: Report
42. W. Viscusi, W. Magat, J. Huber Communication of ambiguous risk information Theory and Decision 31 1991 159 173
43. P.J. Neumann, J.T. Cohen, J.K. Hammitt Willingness to pay for predictive tests with no immediate treatment implications: a survey of U.S. residents Health Economics 2010 Dec 28 [Epub ahead of print]
44. N. Flory, E.V. Lang Distress in the radiology waiting room Radiology 260 2011 166 173
45. F. Sassi, L. Archard, D. McDaid Searching literature databases for health care economic evaluations: how systematic can we afford to be? Med Care 40 2002 387 394
46. L.M. Meckley, D. Greenberg, J.T. Cohen, P.J. Neumann The adoption of cost-effectiveness acceptability curves in cost-utility analyses Med Decis Making 30 2010 314 319
47. C.M. Bell, D.R. Urbach, J.G. Ray Bias in published cost effectiveness studies: systematic review BMJ 332 7543 2006 699 703
48. J. Kievit, V. van d Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation A Markov analysis Cancer 65 1990 2580 2587 (Pubitemid 20168950)
49. J. Hornberger, L.E. Cosler, G.H. Lyman Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer Am J Manag Care 11 2005 313 324 (Pubitemid 40646936)
50. R.P. Walensky, M.C. Weinstein, A.D. Kimmel Routine human immunodeficiency virus testing: an economic evaluation of current guidelines Am J Med 118 2005 292 300 (Pubitemid 40312641)
51. R.H. Ball, A.B. Caughey, F.D. Malone First- and second-trimester evaluation of risk for Down syndrome Obstet Gynecol 110 2007 10 17 (Pubitemid 47015694)
52. M.K. Killie, J. Kjeldsen-Kragh, A. Husebekk, B. Skogen, J.A. Olsen, I.S. Kristiansen Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia BJOG 114 2007 588 595 (Pubitemid 46587959)
53. M. Nielsen, F.J. Hes, H.F. Vasen, W.B. van den Hout Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations BMC Med Genet 8 2007 42
54. K.J. Smith, R.L. Cook, M.S. Roberts Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals Value Health 10 2007 358 366 (Pubitemid 47481107)
55. A. Kowada, O. Takahashi, T. Shimbo, S. Ohde, Y. Tokuda, T. Fukui Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan Mol Diagn Ther 12 2008 235 251
56. L.M. Meckley, D.L. Veenstra Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis Pharmacogenet Genomics 16 2006 139 147 (Pubitemid 43145682)
57. L.N. Venditti, C.P. Venditti, G.T. Berry Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis Pediatrics 112 2003 1005 1015 (Pubitemid 37339550)
58. S.J. Goldie, K.A. Freedberg, M.C. Weinstein, T.C. Wright, K.M. Kuntz Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus Am J Med 111 2001 140 149 (Pubitemid 32728407)
59. N.W. Calvert, A.B. Morgan, J.W. Catto Effectiveness and cost-effectiveness of prognostic markers in prostate cancer Br J Cancer 88 2003 31 35 (Pubitemid 36241214)
60. M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann Oncol 19 2008 487 495 (Pubitemid 351325669)
61. J.S. Mandelblatt, W.F. Lawrence, S.M. Womack Benefits and costs of using HPV testing to screen for cervical cancer JAMA 287 2002 2372 2381 (Pubitemid 34493200)
62. A.J. Sutton, W.J. Edmunds, M.J. Sweeting, O.N. Gill The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis J Viral Hepat 15 2008 797 808
63. A.D. Paltiel, M.C. Weinstein, A.D. Kimmel Expanded screening for HIV in the United States - an analysis of cost-effectiveness N Engl J Med 352 2005 586 595 (Pubitemid 40204671)
64. J.M. Neuner, M.B. Hamel, R.S. Phillips, K. Bona, M.D. Aronson Diagnosis and management of adults with pharyngitis A cost-effectiveness analysis Ann Intern Med 139 2003 113 122 (Pubitemid 38129103)